Schering-Plough, Novartis in Joint Venture
Posted on: Monday, 14 August 2006, 09:00 CDT
New Jersey's Schering-Plough Corp. and Novartis AG are making a once-daily inhaled therapy for asthma and chronic obstructive pulmonary disease.
Schering-Plough's fixed-dose corticosteroid mometasone, the active ingredient in Asmanex, and Novartis' once-daily beta2-agonist indacaterol will be combined in a single inhalation device, company officials said Monday.
The combined product, with once-daily dosing, has the potential to offer patient benefits including enhanced disease control and convenience, Schering-Plough said.
The firms will share development costs and there will be no initial payments by either party. Novartis and Schering-Plough will co-promote the therapy worldwide.
Source: United Press International
Related Articles
- Schering-Plough Reports Financial Results for 2009 Second Quarter
- Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa
- Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD
- J&J, Schering-Plough, Novartis, Bayer vie for Top Honors at the Premier OTC / Healthcare Ad Awards
- Schering-Plough/Novartis's Upcoming Combination Drug for Asthma Will Edge Out Symbicort As the Clinical Gold Standard By 2015
- Schering-Plough Reports Financial Results for 2006 Third Quarter
- Schering-Plough/Novartis: a Winning Combination?
- Schering-Plough Announces Global Agreement With Novartis to Develop Once-Daily Combination Therapy for Asthma and COPD
- Schering-Plough Reports Comparative Pharmacokinetics and Pharmacodynamics Data for PEG-Intron(R) and PEGASYS(R) in Hepatitis C Virus Infection
 |
 |
User Comments (0)
RSS Feeds